ライフサイエンスコーパス: guanylate

1 es a reactive N-silylcarbodiimide capable of guanylating a variety of amines.

2 resence of manganese to form a covalent RtcB-guanylate adduct.

3 The guanylate binding protein (GBP) family of interferon-ind

4 Here, we demonstrate that IFN-inducible guanylate binding protein (Gbp) proteins stimulate caspa

5 rticle, we show that the IFN-gamma-inducible guanylate binding protein 1 (GBP-1) is a regulator of T

6 Although GBP1 (guanylate binding protein 1) was among the first interfe

7 otein that stimulates inflammasome assembly: guanylate binding protein 5 (GBP5).

8 Upon infection, human guanylate binding protein-1 (hGBP1) colocalizes with int

9 that disruption of the SlGBP1 gene, encoding GUANYLATE BINDING PROTEIN1, induces early termination of

10 Members of the guanylate binding proteins (GBP) comprise the most abund

11 Guanylate binding proteins (GBPs) are an interferon (IFN

12 Furthermore, guanylate binding proteins (GBPs) encoded on chromosome

13 Interferon (IFN)-inducible guanylate binding proteins (GBPs) mediate cell-autonomou

14 ase M (IRGM) locus and altered expression of guanylate binding proteins (GBPs) with tuberculosis susc

15 oteins to PVs is controlled by IFN-inducible guanylate binding proteins (GBPs), which themselves dock

16 till controlled in HFFs deficient in the p65 guanylate binding proteins GBP1 or GBP2 and the autophag

17 wing number of regulatory networks involving guanylate binding proteins, protein kinases, ubiquitylat

18 examined a complete mouse 65-kilodalton (kD) guanylate-binding protein (Gbp) gene family as part of a

19 ll lines, resulting in the identification of guanylate-binding protein 1 (GBP1) as a potent anti-CSFV

20 library of porcine ISGs, we identify porcine guanylate-binding protein 1 (GBP1) as a potent antiviral

21 The human guanylate-binding protein 1 (hGBP1) belongs to the dynam

22 Human guanylate-binding protein 1 (hGBP1), the founding member

23 e-like activity factor, and interaction with guanylate-binding protein 1, a host cell factor involved

24 Guanylate-binding protein 2 (GBP2) is an interferon-indu

25 milies in different cell types is the 65-kDa guanylate-binding protein family that is recruited to th

26 man myxovirus resistance protein A and human guanylate-binding protein-1 as markers for the different

27 Patients with primary tumors expressing only guanylate-binding protein-1 exhibited the highest cancer

28 as exclusively induced by IFN-alpha, whereas guanylate-binding protein-1 was strongly induced by IFN-

29 actor IRF5, which upregulates genes encoding guanylate-binding proteins (GBPs) and inducible nitric o

30 Guanylate-binding proteins (GBPs) are interferon (IFN)-i

31 ow that in interferon-gamma-stimulated cells guanylate-binding proteins (GBPs) assemble on the surfac

32 that the interferon-induced GTPase family of guanylate-binding proteins (GBPs) coats Shigella flexner

33 Guanylate-binding proteins (GBPs) have recently emerged

34 al. demonstrate a critical role for the p65 guanylate-binding proteins (GBPs) in this process during

35 geted by immunity-related GTPases (IRGs) and guanylate-binding proteins (GBPs) upon their induction b

36 IRGM proteins affect the localization of the guanylate-binding proteins (GBPs), a second family of in

37 proteins, the immunity-related GTPases, the guanylate-binding proteins (GBPs), and the very large IF

38 I IFN-associated genes, such as IFN-beta and guanylate-binding proteins (GBPs), are downregulated in

39 An IFN-inducible family of DLPs, the guanylate-binding proteins (GBPs), is involved in antimi

40 ssion of IRF1, which drove the expression of guanylate-binding proteins (GBPs); this led to intracell

41 We show that guanylate-binding proteins are recruited to intracellula

42 family of interferon-induced GTPases called 'guanylate-binding proteins' (GBPs).

43 interferon-inducible GTPases, the so-called guanylate-binding proteins, is required for the full act

44 asmic bacteria through a mechanism requiring guanylate-binding proteins.

45 exposure to g-interferon, including several guanylate-binding proteins.

46 ch as IFN-beta, IFN regulatory factor 1, and guanylate-binding proteins.

47 rmans GMP synthase, the second enzyme in the guanylate branch of de novo purine biosynthesis.

48 Bis-(3',5') cyclic di-guanylate (c-di-GMP) is a key bacterial second messenger

49 ein 3 (RD3) is critical in the regulation of guanylate cyclase (GC) signaling and photoreceptor cell

50 studied before and after: (1) inhibition of guanylate cyclase (GC) with and without a NO donor; (2)

51 ny biological effects of NPs are mediated by guanylate cyclase (GC)-coupled NP receptors, NPR-A and N

52 gene encoding the alpha subunit of a soluble guanylate cyclase (Gucy1A3).

53 nNOS and its receptor, guanylate cyclase (NO-GC), are expressed in somata of T-

54 xide (NO) activates the NO-sensitive soluble guanylate cyclase (NO-GC, sGC) and triggers intracellula

55 assembled domains of nitric oxide-sensitive guanylate cyclase (NOsGC) remains to be determined.

56 or neutral results), NO-independent soluble guanylate cyclase (sGC) activation, or enhancement of sG

57 Belonging to the class of so-called soluble guanylate cyclase (sGC) activators, cinaciguat and BAY 6

58 in (GTN), resulting in activation of soluble guanylate cyclase (sGC) and cGMP-mediated vasodilation.

59 Epigenetic regulation of soluble guanylate cyclase (sGC) beta1 in breast cancer cells.

60 insertion into the beta1 subunit of soluble guanylate cyclase (sGC) beta1, which enables it to assoc

61 Activation of soluble guanylate cyclase (sGC) by the signaling molecule nitric

62 ges of heme coordination in purified soluble guanylate cyclase (sGC) by time-resolved spectroscopy in

63 Soluble guanylate cyclase (sGC) catalyzes the conversion of guan

64 Soluble guanylyl/guanylate cyclase (sGC) converts GTP to cGMP after bindi

65 Stimulators of soluble guanylate cyclase (sGC) enhance NO signaling; have been

66 RATIONALE: Soluble guanylate cyclase (sGC) heme iron, in its oxidized state

67 uanidine; 10 mumol l(-1) , n = 6) or soluble guanylate cyclase (sGC) inhibitor ODQ (1H-[1,2,4]oxadiaz

68 Soluble guanylate cyclase (sGC) is a heme-containing enzyme that

69 Soluble guanylate cyclase (sGC) is a heterodimer composed of alp

70 Soluble guanylate cyclase (sGC) is the mammalian endogenous nitr

71 Soluble guanylate cyclase (sGC) is the primary nitric oxide (NO)

72 Soluble guanylate cyclase (sGC) is the primary receptor for nitr

73 The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recentl

74 ery pressure encodes an alpha1-A680T soluble guanylate cyclase (sGC) variant.

75 Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxid

76 (ODQ) resulted in heme oxidation of soluble guanylate cyclase (sGC), as evident from diminished NO-i

77 loss of the prosthetic haem group of soluble guanylate cyclase (sGC), preventing its activation by ni

78 or a related species that activates soluble guanylate cyclase (sGC), resulting in cGMP-mediated vaso

79 be eliminated by inhibiting hepatic soluble guanylate cyclase (sGC), suggesting that the sGC pathway

80 Soluble guanylate cyclase (sGC), the mammalian NO sensor, transd

81 Soluble guanylate cyclase (sGC), the primary NO receptor, trigge

82 The downstream target of NO, soluble guanylate cyclase (sGC), was in somata in the inner and

83 ing the airway smooth muscle enzyme, soluble guanylate cyclase (sGC).

84 ignaling proteins in cells including soluble guanylate cyclase (sGC).

85 unctions as the primary activator of soluble guanylate cyclase (sGC).

86 tion of BAY 60-2770, an activator of soluble guanylate cyclase (sGC).

87 ctivity of the downstream NO target, soluble guanylate cyclase (sGC).

88 through activation of the soluble isoform of guanylate cyclase (sGC).

89 tor component, the alpha1 subunit of soluble guanylate cyclase (sGCalpha1), are prone to hypertension

90 protein-coupled receptor kinase 1 (GRK1) and guanylate cyclase 1 (GC1) has been suggested to play a r

91 ophy caused by loss-of-function mutations in guanylate cyclase 1 (GC1), a key member of the phototran

92 Depletion of cGMP by deleting retinal guanylate cyclase 1 or inhibition of PKG using chemical

93 ignaling (Nitric Oxide Synthase 3 [NOS3] and Guanylate Cyclase 1, Soluble, Alpha 3 [GUCY1A3]) with a

94 in 2); glucokinase (hexokinase 4) regulator; guanylate cyclase 1, soluble, beta 3; MYST histone acety

95 s (GCAP1 and GCAP2) to their membrane target guanylate cyclase 1.

96 ing identified a single-base substitution in guanylate cyclase 2D, membrane (retina-specific) gene (G

97 -deficient mice (moderate achromatopsia) and guanylate cyclase 2e-deficient mice (LCA with slower con

98 eotide-gated channel B subunit-deficient and guanylate cyclase 2e-deficient mice decreased about 40%

99 eme- and NO-independent activator of soluble guanylate cyclase [4-([(4-carboxybutyl)[2-(5-fluoro-2-([

100 to show a direct association between RD3 and guanylate cyclase activating protein 1 (GCAP1).

101 Modulated by Ca(2+) sensors guanylate cyclase activating proteins 1 and 2 (GCAP1 and

102 Treatment with the soluble guanylate cyclase activator BAY41-2272, a vasorelaxing a

103 hodiesterase-5 inhibitors, and now a soluble guanylate cyclase activator have increased therapeutic o

104 We show that the guanylate cyclase activator, riociguat, a novel treatmen

105 The guanylate cyclase activator, riociguat, enhanced current

106 as phosphodiesterase (PDE)-5 inhibitors and guanylate cyclase activators may represent a promising t

107 activity kinase that has in vitro kinase and guanylate cyclase activities.

108 l-specific knockout of the ANP receptor with guanylate cyclase activity (betaGC-A-KO).

109 esponses, whereas in Arabidopsis, OsWAKL21.2 guanylate cyclase activity activates these responses.

110 Blocking soluble guanylate cyclase activity completely suppresses neurite

111 In summary, the loss or gain of guanylate cyclase activity for these NPR1 allelic varian

112 Therefore, the guanylate cyclase activity of BRI1 is modulated by the k

113 s containing bacterial H-NOX domains exhibit guanylate cyclase activity, but this activity is not inf

114 diazolo[4,3-a]quinoxalin-1-one, a blocker of guanylate cyclase activity.

115 r inhibition of protein kinase A nor soluble guanylate cyclase altered this contractile response.

116 sociation of nitric oxide synthase 1/soluble guanylate cyclase and a higher production of cyclic guan

117 Pharmacological inhibition of soluble guanylate cyclase and NOS activity rapidly induces neuri

118 that requires an atypical O2-binding soluble guanylate cyclase and that is sustained until oxygen lev

119 1) Both nitric oxide synthase 1 and soluble guanylate cyclase are expressed in higher levels in vasc

120 ide/oxygen-binding (H-NOX) domain of soluble guanylate cyclase as a selective NO sensor.

121 Guanylate cyclase C (GC-C) is a transmembrane receptor t

122 Guanylate Cyclase C (GC-C) is an apically-oriented trans

123 osome 12 and then sequenced GUCY2C, encoding guanylate cyclase C (GC-C), an intestinal receptor for b

124 activating mutations in intestinal receptor guanylate cyclase C (GC-C), the genetic cause for the ma

125 Guanylate cyclase C (GUCY2C or GC-C) and its ligands, gu

126 Guanylate cyclase C (GUCY2C) and its hormones guanylin a

127 gous to paracrine hormones of the intestinal guanylate cyclase C (GUCY2C) receptor.

128 out cross-reacting with the human endogenous guanylate cyclase C receptor ligands.

129 a minimally absorbed peptide agonist of the guanylate cyclase C receptor.

130 is an active kinase and also encapsulates a guanylate cyclase catalytic centre.

131 Mutating the guanylate cyclase center of PSKR1 impairs seedling growt

132 A guanylate cyclase construct containing the juxta-membran

133 affects the efficacy of soluble/particulate guanylate cyclase coupling to cGMP in cardiac dysautonom

134 n did wild-type Brucella or the low-c-di-GMP guanylate cyclase DeltacgsB mutant.

135 o be observed for any member of the membrane guanylate cyclase family.

136 opportunities aimed at activation of soluble guanylate cyclase for multiple cardiovascular indication

137 BAG transduction pathway, the receptor-type guanylate cyclase GCY-9, suffices to confer cellular sen

138 ing of a sensory receptor, the receptor-type guanylate cyclase GCY-9, to cilia in chemosensory neuron

139 These neurons express the soluble guanylate cyclase Gucy1b2 and the cation channel Trpc2.

140 than those of dopamine and depend on soluble guanylate cyclase in postsynaptic Kenyon cells.

141 psis, whereas levels and activity of soluble guanylate cyclase increase.

142 2)O(2)-induced dilation, whereas the soluble guanylate cyclase inhibitor ODQ had no effect.

143 is also unknown how binding of NO to heme in guanylate cyclase is communicated to the catalytic domai

144 of mice lacking one of the two NO-sensitive guanylate cyclase isoforms [NO-GC1 knockout (KO) or NO-G

145 hibited pathological differentiation via the guanylate cyclase NPR2 (natriuretic peptide receptor 2)

146 e current study the conformational change of guanylate cyclase on activation by NO was studied using

147 , as occurs at the Fe(2+) centres of soluble guanylate cyclase or cytochrome c oxidase.

148 iomyocyte cGMP synthesis via an eNOS/soluble guanylate cyclase pathway.

149 n of COX, but was independent of the soluble guanylate cyclase pathway.

150 rived nitric oxide and activation of soluble guanylate cyclase promotes endothelial quiescence and go

151 ide is a novel therapeutic agent, which is a guanylate cyclase receptor agonist that stimulates water

152 tients, with associated increases in soluble guanylate cyclase responsiveness to NO.

153 target proteins beta-PIX, plakophilin-4, and guanylate cyclase soluble subunit alpha-2 using colocali

154 ervious pulmonary embolism, treatment with a guanylate cyclase stimulator normalized pulmonary hemody

155 Among patients with HFpEF, the soluble guanylate cyclase stimulator praliciguat, compared with

156 rectomy (PEA) who were receiving the soluble guanylate cyclase stimulator riociguat.

157 ulmonary vasodilator reserve using a soluble guanylate cyclase stimulator, BAY 41-8543.

158 Riociguat, a soluble guanylate cyclase stimulator, has been shown in a phase

159 e effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart fai

160 f diabetes status, and vericiguat, a soluble guanylate cyclase stimulator, reduces heart failure hosp

161 efficacy and safety of a novel oral soluble guanylate cyclase stimulator, vericiguat, on quality of

162 hypothesized that riociguat, a novel soluble guanylate cyclase stimulator, would have beneficial hemo

163 member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previo

164 drugs are being evaluated, including soluble guanylate cyclase stimulators, phosphodiesterase type 5

165 sts, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin analogues, a

166 liseconds, cGMP is relayed from the receptor guanylate cyclase to a cGMP-gated channel that serves as

167 and GCAP2 to the full-length membrane-bound guanylate cyclase type 1.

168 between nitric oxide synthase 1 and soluble guanylate cyclase were determined.

169 AP2 bound to different regions on the target guanylate cyclase with submicromolar affinity (apparent

170 The homeobox gene Emx1 is expressed in three guanylate cyclase(+) populations, two located in the MOE

171 receptor ROS-GC1 (rod outer segment membrane guanylate cyclase) is a vital component of phototransduc

172 itric oxide synthase 1 (and possibly soluble guanylate cyclase) may represent a valuable alternative

173 eraction with specific targets (e.g. soluble guanylate cyclase) or through the generation of secondar

174 ANF-RGC is the prototype membrane guanylate cyclase, both the receptor and the signal tran

175 tric oxide synthase 1, nitric oxide, soluble guanylate cyclase, cyclic GMP (cGMP), and PKG.

176 rtension, riociguat, a stimulator of soluble guanylate cyclase, has proven efficacious.

177 by the kinase while cGMP, the product of the guanylate cyclase, in turn inhibits BRI1 kinase activity

178 cological inhibitors of NO synthase, soluble guanylate cyclase, or cGMP-dependent protein kinases (PK

179 P2Y12 GPVI, PAR1/PAR4, TP, IP receptors, and guanylate cyclase, respectively, in Factor Xa-inhibited

180 l delivery of AAV5 vectors containing murine guanylate cyclase-1 (GC1) cDNA driven by either photorec

181 Treatment with PKG inhibitor and deletion of guanylate cyclase-1 (GC1), the enzyme producing cGMP in

182 e elucidated this dependency by showing that guanylate cyclase-1 is a novel rhodopsin-binding protein

183 Indeed, we demonstrated that guanylate cyclase-1, producing the cGMP second messenger

184 ons in GUCY2D, the gene that encodes retinal guanylate cyclase-1.

185 sites (EF-hands) of the GUCA1A gene encoding guanylate cyclase-activating protein 1 (GCAP1) cause slo

186 o the amino acid substitution p.L176F in the guanylate cyclase-activating protein 1 (GCAP1).

187 We tested direct binding of guanylate cyclase-activating proteins (GCAP1 and GCAP2)

188 Guanylate cyclase-activating proteins (GCAPs) link cGMP

189 ylin in the brain and activates the receptor guanylate cyclase-C (GC-C) to reduce food intake and pre

190 n these patients presumably by activation of guanylate cyclase-C (GC-C), which stimulates production

191 naclotide is a minimally absorbed agonist of guanylate cyclase-C (GUCY2C or GC-C) that reduces sympto

192 iac natriuretic peptides ANP and BNP and the guanylate cyclase-linked natriuretic peptide receptors N

193 ration through activation of the particulate guanylate cyclase-linked natriuretic peptide receptors N

194 ly to enhance GABA release through a soluble guanylate cyclase-mediated pathway.

195 from targeting of the haem moiety of soluble guanylate cyclase.

196 st sensitive target of NO signaling, soluble guanylate cyclase.

197 ivate, and the subsequent generation cGMP by guanylate cyclase.

198 in sepsis and its relationship with soluble guanylate cyclase.

199 s a vital ANF signal transducer motif of the guanylate cyclase.

200 ers include the mammalian NO sensor, soluble guanylate cyclase.

201 on of NO synthase or the NO receptor soluble guanylate cyclase.

202 an higher apparent affinity with its target guanylate cyclase.

203 ibitors of Gbetagamma, Akt, NOS, and soluble guanylate cyclase.

204 enated myoglobin activates canonical soluble guanylate cyclase/cGMP signaling pathways.

205 ansmitter release from photoreceptors by the guanylate cyclase/PDE6 pair in phototransduction.

206 rons counterbalance each other via different guanylate cyclases (GCYs) to control lifespan balance.

207 Soluble guanylate cyclases (sGCs) are gas-binding proteins that

208 Significance statement: Soluble guanylate cyclases (sGCs) control essential and diverse

209 A canonical Galpha-protein, together with guanylate cyclases and cGMP-gated channels, is needed fo

210 litating the stability and/or trafficking of guanylate cyclases and maintaining ER and mitochondrial

211 y NO, CO, and O(2), suggesting that atypical guanylate cyclases and NO-sensitive guanylate cyclases h

212 ical and novel NIT-domain containing soluble guanylate cyclases as putative NO/nitrite/nitrate sensor

213 Rom1 or peripherin/rds; however, the retinal guanylate cyclases GC1 and GC2 were severely affected in

214 atypical guanylate cyclases and NO-sensitive guanylate cyclases have a common molecular mechanism for

215 Atypical soluble guanylate cyclases mediating O(2) responses also contrib

216 Our data suggest GLB-5 and the soluble guanylate cyclases operate in close proximity to sculpt

217 ation of GCY-33 and GCY-35, atypical soluble guanylate cyclases that act as O2 sensors, to the dendri

218 cyclic GMP-gated cation channels and distal guanylate cyclases.

219 rget, since it maintains the balance between guanylate deoxynucleotide and ribonucleotide levels that

220 by combining citric acid (CA) and disodium 5-guanylate (DG).

221 y for adenylate and is unable to incorporate guanylate into RNA products, which strongly argues again

222 role of the Discs large/membrane-associated guanylate kinase (Dlg/MAGUK) family of scaffolding prote

223 phosphorylation of PSD-95 at Ser-561 in its guanylate kinase (GK) domain, which is mediated by the p

224 SAP102 contains PDZ, SH3, and guanylate kinase (GK)-like domains, which mediate specif

225 e molecular interaction between (p)ppGpp and guanylate kinase (GMK), revealing the importance of this

226 3 (SH3) domain, and a region of homology to guanylate kinase (GUK); the structure of this core motif

227 Human guanylate kinase (hGMPK) is the only known enzyme respon

228 s, the discs large (DLG)-membrane-associated guanylate kinase (MAGUK) family of scaffolding proteins

229 ptic density-95 (PSD-95) membrane-associated guanylate kinase (MAGUK) family of scaffolding proteins

230 KEY POINTS: The membrane-associated guanylate kinase (MAGUK) family of synaptic scaffolding

231 The membrane-associated guanylate kinase (MAGUK) family of synaptic scaffolding

232 termined previously that membrane-associated guanylate kinase (MAGUK) protein discs large homolog 5 (

233 of the Discs large (DLG)-membrane-associated guanylate kinase (MAGUK) protein family regulate these p

234 t excitatory synapses by membrane-associated guanylate kinase (MAGUK) proteins regulates synapse deve

235 he zonula occludens (ZO) membrane-associated guanylate kinase (MAGUK) proteins ZO-1, -2, and -3.

236 ayed impaired binding to membrane-associated guanylate kinase (MAGUK) proteins.

237 he PDZ domain-containing Membrane-associated Guanylate Kinase (MaGUK) PSD93 as a direct ZDHHC14 inter

238 ptors and enzymes around Membrane Associated Guanylate Kinase (MAGUK) scaffold proteins are a paradig

239 reported to bind to the membrane-associated guanylate kinase (MAGUK) scaffolding proteins, as well a

240 itment domain-containing membrane-associated guanylate kinase 1 (CARMA1) and/or the Toll-like recepto

241 spase-recruitment domain membrane-associated guanylate kinase 1 (CARMA1) signalosome through the coor

242 membrane complex with a membrane-associated guanylate kinase and AKAP5, which constitutively attenua

243 revealed that specific amino acid changes in guanylate kinase and in the beta and beta' subunits of R

244 analyzed the dynamic behavior of the enzyme guanylate kinase as it evolved into the GK protein inter

245 SD-95 is a member of the membrane-associated guanylate kinase class of proteins that forms scaffoldin

246 nts revealed 2 binding surfaces on the beta4 guanylate kinase domain contributing to a 156 +/- 18 mic

247 a loss-of-function mutant mouse lacking the guanylate kinase domain of PSD-95 (PSD-95(GK)), we analy

248 A fragment comprising the SH3 domain and the guanylate kinase domain of synapse-associated protein 10

249 /Discs large/ZO-1 (PDZ)-Src homology 3 (SH3)-guanylate kinase domain sequence.

250 ort polybasic segment at the boundary of the guanylate kinase domain that slows down channel inactiva

251 -Subunits contain one Src homology 3 and one guanylate kinase domain, flanked by variable regions wit

252 ramolecular interactions between the SH3 and guanylate kinase domains play a role in the stability of

253 lg1, zona occludens-1) domains, the PDZ3 and guanylate kinase domains were required.

254 ined beta isoforms, which consist of SH3 and guanylate kinase domains.

255 The guanylate kinase enzyme (GK(enz)), which catalyzes phosp

256 he leading member of the membrane-associated guanylate kinase family of proteins, which are defined b

257 (CLMP), occludin (OCLN), membrane-associated guanylate kinase inverted 1 (MAGI1), and MAGI2 mRNA expr

258 ule (S-SCAM; also called membrane-associated guanylate kinase inverted-2 and atrophin interacting pro

259 itment domain-containing membrane-associated guanylate kinase protein (CARMA)3 is specifically expres

260 t serine protein kinase; membrane-associated guanylate kinase protein (MAGI)-1, MAGI-2, and MAGI-3],

261 We show here that membrane-associated guanylate kinase protein Dlg5 is required for proper bra

262 and other members of the membrane-associated guanylate kinase protein family, as well as Scribble.

263 , we have identified the membrane-associated guanylate kinase protein membrane palmitoylated protein

264 major glutamate receptor membrane-associated guanylate kinase scaffolds expressed in the young superf

265 d inositol trisphosphate receptor-associated guanylate kinase substrate (IRAG, Mrvi1, and Jaw1L) are

266 scaffold protein called membrane-associated guanylate kinase with inverted orientation (Magi)-1.

267 ntaining protein MAGI-1 (membrane-associated guanylate kinase with inverted orientation protein-1) an

268 Discs Large 1, a MAGUK (Membrane Associated Guanylate Kinase) family member that is the highly conse

269 nd recruitment of MAGUK (membrane-associated guanylate kinase) scaffolding proteins or NMDA receptors

270 overlaps with its MAGUK (membrane-associated guanylate kinase)-binding domain.

271 ng HIV-reverse transcriptase (RT), adenylate/guanylate kinase, and human DNA polymerase gamma.

272 itment domain-containing membrane-associated guanylate kinase, initiates a unique signaling cascade v

273 PSD-95, a membrane-associated guanylate kinase, is the major scaffolding protein at ex

274 PSD-95, a membrane-associated guanylate kinase, is the major scaffolding protein in th

275 s, we found that loss of membrane associated guanylate kinase, WW and PDZ domain containing 2 and pro

276 ase-causing mutations in membrane-associated guanylate kinase, WW, and PDZ domain-containing 2 (MAGI2

277 Here we report that guanylate kinase-associated protein (GKAP; also known as

278 are formed by a Src homology 3 domain and a guanylate kinase-like (GK) domain connected through a va

279 h consists of PDZ, Src homology 3 (SH3), and guanylate kinase-like domains.

280 TF, the association of "membrane-associated guanylate kinase-with inverted configuration" (MAGI)1-3

281 Membrane-associated guanylate kinases (MAGUKs) are a family of scaffolding p

282 Membrane-associated guanylate kinases (MAGUKs) are major components of the p

283 nsity (PSD)-95 family of membrane-associated guanylate kinases (MAGUKs) are major scaffolding protein

284 The Membrane Associated Guanylate Kinases (MAGuKs) are scaffold proteins at cell

285 dance of PSD-95 or other membrane-associated guanylate kinases (MAGUKs) drives the bidirectional chan

286 (discs large) family of membrane-associated guanylate kinases (MAGUKs) that are components of the po

287 Membrane-associated guanylate kinases (MAGUKs), including SAP102, PSD-95, PS

288 large (DLG) subfamily of membrane-associated guanylate kinases (MAGUKs).

289 n-binding domain found in membrane associate guanylate kinases that function in mitotic spindle orien

290 GPR30 interacted with membrane-associated guanylate kinases, including SAP97 and PSD-95, and prote

291 d recruitment domain and membrane-associated guanylate-like kinase domain-containing protein 3; membr

292 ing proteins include the membrane-associated guanylate-like kinases [postsynaptic density protein of

293 ent inhibition of invasion to suppression of guanylate metabolism.

294 ity to potentiate the vasodilatory NO/cyclic guanylate monophosphate signaling pathway, we assessed w

295 We find that pharmacological inhibitors of guanylate nucleotide synthesis have selective deleteriou

296 ction maintaining the cellular adenylate and guanylate nucleotide.

297 aasl knock-out and consequent starvation for guanylate nucleotides.

298 or balancing the intracellular adenylate and guanylate pools.

299 we find that purine metabolites, especially guanylates, strongly correlate with radiation resistance

300 idinyl-N)-GMP intermediate; (ii) transfer of guanylate to a polynucleotide 3'-phosphate to form a pol